News | June 10, 2022
Olema Oncology and Aurigene collaboration to discover and develop novel cancer therapies
During the research term, Olema will contribute funding to Aurigene to facilitate ongoing discovery efforts.
During the research term, Olema will contribute funding to Aurigene to facilitate ongoing discovery efforts.
Ivacaftor Tablets had estimated annual sales of USD 109 million in the US.
If approved, Tafinlar + Mekinist may offer a potential new standard-of-care for pediatric patients with this brain cancer
The new subsidiary follows the recent announcement of Tetra's partnership with Cannvalate Pty Ltd for the performance of clinical trials of Tetra's drug candidates in Australia.
Scemblix (asciminib) continues to show superior efficacy with more-than-two-fold improvement in major molecular response rate vs. Bosulif (bosutinib) at 96 weeks
The Innopack confex is a perfect platform for exhibitors to demonstrate their latest developments in the fields of pharmaceutical packaging, labelling, drug delivery device design and engineering.
he Phase 2 TIDAL data generated to date continue to highlight zandelisib's therapeutic profile and the potential to benefit patients
The DMF#36513 demonstrates ANP’s success in the development of its “Plug and Play” drug delivery platform.
Operations at Oakville, Canada manufacturing plant expected to end by first quarter 2023
To address the preventive & primary healthcare delivery gaps in India
Subscribe To Our Newsletter & Stay Updated
